Related Experiment Video
Updated: Oct 7, 2025
04:04
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.6K
Practical Management of Oligometastatic Non-Small-Cell Lung Cancer
Katie Jasper1,2, Brendon Stiles3, Fiona McDonald4
1Division of Radiation Oncology, Western University, London Health Sciences Centre, London, Canada.
Summary
Local ablative therapies like surgery and stereotactic radiotherapy improve survival for non-small-cell lung cancer patients with limited metastatic spread. This review guides optimal treatment selection for oligometastatic disease.
Area of Science:
- Oncology
- Radiation Oncology
- Thoracic Surgery
Background:
- Oligometastatic non-small-cell lung cancer (NSCLC) presents a unique clinical challenge.
- Local ablative therapies are increasingly utilized for this condition.
Purpose of the Study:
- To review current evidence on the efficacy of local ablative therapies for oligometastatic NSCLC.
- To provide a framework for guiding treatment decisions in managing oligometastatic NSCLC.
Main Methods:
- Systematic review of recent randomized controlled trials.
- Analysis of progression-free survival and overall survival data.
- Discussion of upcoming Phase III trial outcomes.
Main Results:
- Local ablation, including surgery and SABR, demonstrates benefits in progression-free and overall survival.
- Emerging data will further refine understanding of optimal treatment conditions.
Conclusions:
- Local ablative therapies are integral to treating oligometastatic NSCLC.
- A framework is proposed to identify optimal patient, tumor, and treatment characteristics for management.
